for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Abcam Plc

ABCA.L

Latest Trade

1,173.00GBp

Change

1.00(+0.09%)

Volume

471,995

Today's Range

1,168.00

 - 

1,192.00

52 Week Range

1,006.00

 - 

1,523.00

As of on the SEATS (AIM Market) ∙ Minimum 15 minute delay

Pricing

Previous Close
1,172.00
Open
1,191.00
Volume
471,995
3M AVG Volume
9.46
Today's High
1,192.00
Today's Low
1,168.00
52 Week High
1,523.00
52 Week Low
1,006.00
Shares Out (MIL)
205.74
Market Cap (MIL)
2,413.29
Forward P/E
37.03
Dividend (Yield %)
--

Next Event

Dividend For ABCA.L - 8.5800 GBX

Latest Developments

More

Abcam FY Pretax Profit Falls 18.4% To 56.4 Mln Stg

Abcam Says CFO Gavin Wood To Step Down

Abcam Sees FY Rev, Gross Margin To Be Higher Than Last Yr

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Abcam Plc

Abcam plc is a global life sciences company. As a developer of reagents and tools, the Company's purpose is to serve life science researchers globally. Providing the research and clinical communities with tools and scientific support, the Company offers validated biological binders and assays to address important targets in critical biological pathways. The Company is engaged in data sharing and ecommerce in the life sciences. The Company focuses on helping advance global understanding of biology and causes of disease, which, in turn, will drive new treatments and improved health. Two-thirds of the world's 750,000 life science researchers use its affinity binders, reagents, biomarkers and assays and the Company's products are mentioned in over 20,000 of the 56,000 peer-reviewed papers published each year in the life sciences. It has approximately 10 locations located in the world, through life science research hubs, enabling local services and multi-language support.

Industry

Biotechnology & Drugs

Contact Info

Clifford Allbutt Building

Cambridge Biomedical Campus, Hills Road

+44.1223.696000

http://www.abcam.com/

Executive Leadership

Peter Vance Allen

Non-Executive Chairman of the Board

Alan Thomas Hirzel

Chief Executive Officer, Executive Director

Jonathan Simon Milner

Non-Executive Deputy Chairman of the Board

Gavin Hilary James Wood

Chief Financial Officer, Executive Director

Marc Perkins

Interim Company Secretary

Key Stats

2.56 mean rating - 9 analysts
Sell
Hold
Buy
Revenue (MM, GBP)

2017

0.2K

2018

0.2K

2019

0.3K

2020(E)

0.3K
EPS (GBp)

2017

25.460

2018

32.400

2019

32.600

2020(E)

31.678
Price To Earnings (TTM)
53.64
Price To Sales (TTM)
9.29
Price To Book (MRQ)
6.27
Price To Cash Flow (TTM)
39.82
Total Debt To Equity (MRQ)
--
LT Debt To Equity (MRQ)
--
Return on Investment (TTM)
11.78
Return on Equity (TTM)
10.49

Latest News

BRIEF-Abcam Says Proposal Made To Horizon Discovery Regarding Possible Offer For Horizon Has Been Rejected

* MADE A PROPOSAL TO BOARD OF HORIZON DISCOVERY IN RELATION TO A POSSIBLE OFFER FOR HORIZON DISCOVERY AT A VALUE OF 181P PER HORIZON DISCOVERY SHARE

BRIEF-Abcam Posts HY Pretax Profit Of 32.8 Mln STG

* H1 TOTAL REVENUE GROWTH OF 9.8% ON A REPORTED BASIS TO £112.5M

UK's Abcam signs licensing deal with Roche; shares rise

British biotechnology firm Abcam Plc said on Monday it signed a deal with Roche Holding AG to get rights to a portfolio of the Swiss drugmaker's research products in its life science division.

BRIEF-Abcam Says Entered Into License Agreement With Roche​

* HAS ENTERED INTO A DEFINITIVE LICENSE AGREEMENT WITH ROCHE

BRIEF-Abcam Says Signed Exclusive License Agreement with Roche

* HAS ENTERED INTO A DEFINITIVE LICENSE AGREEMENT WITH ROCHE

BRIEF-Abcam Says On Track TO DELIVER 10% FY CONSTANT CURRENCY REVENUE GROWTH

* ABCAM PLC - WE EXPECT TO REPORT REVENUE GROWTH FOR FIRST HALF OF APPROXIMATELY 11 PCT

BRIEF-Abcam's Murray Hennessy to step down from non-executive chairman position

* CHAIRMAN, MURRAY HENNESSY, HAS INFORMED BOARD THAT HE HAS ACCEPTED A CEO ROLE

BRIEF-Abcam posts FY pretax profit 51.9 mln stg

* TOTAL DIVIDEND 10.18 PENCEPER SHARE Source text for Eikon: Further company coverage: (Bangalore.newsroom@thomsonreuters.com)

BRIEF-Abcam H1 pretax profit rises

* H1 pretax profit 25.1 million stg versus 20.9 million stg year ago

BRIEF-Abcam speeds up performance milestones for product technology development

* Further to acquisition of Axiomx, agreed to accelerate certain performance milestones associated with development of product technology

BRIEF-Abcam says current year has started well

* Current year has started well and we are making good progress against our strategic priorities and growth objectives - chairman

BRIEF-Abcam commits to lease of facility on Cambridge Biomedical Campus

* Commits to lease of a new facility on Cambridge Biomedical Campus Source text for Eikon: Further company coverage:

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up